IW 384

July 19, 2026 Viktor Zarev 0 min read
  1. Biopharma firms ride high into Q2 earnings season. 
  2. UnitedHealthcare beats expectations with Q2 financials. 
  3. Are payors backing away from pledges to reform prior authorization? 
  4. U.S. Senate votes to save WISeR prior auth pilot project.
  5. Hospitals look for help to automate RCM processes. 
  6. FDA officials retreat from policy guidelines from previous officials. 
  7. Is data on ultrasound-directed gene therapy “too good to be true?”
  8. Deaths from coronary artery disease fall in U.S. 
  9. Editors at diabetes journal rebel after claiming censorship. 
  10. California farm linked to cyclosporiasis outbreak preps wider recall.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions August 13, 2026

More Interventional Cardiologists, More Low-Value Stents August 13, 2026

The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.

Cardiology Business August 10, 2026

iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026

iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.

Cardiology Pharmaceuticals August 6, 2026

ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026

Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.